Lineage Cell Therapeutics to Present at FORCE Wealth Virtual Fireside Chat on September 23, 2020
17 September 2020 - 10:00PM
Business Wire
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing novel cell
therapies for unmet medical needs, announced today that Brian M.
Culley, Chief Executive Officer, and Brandi L. Roberts, Chief
Financial Officer, will be participating in a FORCE Wealth Virtual
Fireside Chat on September 23, 2020 at 12:00 pm Eastern Time / 9:00
am Pacific Time. Jason McCarthy, Ph.D., Senior Managing Director,
Biotechnology, Maxim Group, LLC will host the fireside chat with
Lineage management.
Interested investors can access the live presentation on the
Events and Presentations section of Lineage’s website and archived
presentations will be available for 30 days. Additional videos are
available on the Media page of the Lineage website, located at
www.lineagecell.com/media/.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC, an allogeneic dendritic cell therapy platform for
immuno-oncology and infectious disease, currently in clinical
development for the treatment of non-small cell lung cancer and in
preclinical development for additional cancers and as a vaccine
against infectious diseases, including SARS-CoV-2, the virus which
causes COVID-19. For more information, please visit
www.lineagecell.com or follow the Company on Twitter
@LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200917005214/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Apr 2024 to May 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From May 2023 to May 2024